Glenmark gets licensing deal boost
It is another significant deal from Glenmark Pharma. This time it is extending its earlier partnership with Sanofi Aventis for a second molecule for $613 million with upfront payments of $50 million. New molecule GBR 500 is being developed for auto immune diseases and is expected to be commercialised by 2017.
![Gadgets 360 With Technical Guruji: Ask TG [June 1, 2024]](https://c.ndtvimg.com/2024-06/7jvriahc_ask-tg_640x480_01_June_24.jpg?downsize=355∶533 "Gadgets 360 With Technical Guruji: Ask TG [June 1, 2024]")
![Gadgets 360 With Technical Guruji: Tech Tip [June 1, 2024]](https://c.ndtvimg.com/2024-06/115lbi0g_tech-tip_640x480_01_June_24.jpg?downsize=355∶533 "Gadgets 360 With Technical Guruji: Tech Tip [June 1, 2024]")
